Ruxolitinib 20mg (Ruxolitinib)

Contact us for more information
Wishlist Compare
Brand nameJakaviInternational trade nameJakafiActive substanceRuxolitinibStrength20mgCategoryAnti Cancer

Description of Jakavi 20mg (Ruxolitinib 20mg)

Jakavi 20mg (Ruxolitinib 20mg) belongs to the type of targeted therapy. It is an oral receptor tyrosine kinase inhibitor. It acts by inhibiting certain enzymes in the body which affect blood cell production.

Jakavi 20mg (Ruxolitinib 20mg) is prescription medicine provided under supervision of doctors or pharmacists.

Medical use /Indication of Jakavi 20mg (Ruxolitinib 20mg)

Jakavi 20mg (Ruxolitinib 20mg) is indicated for the treatment in patients with intermediate and high-risk myelofibrosis.

Mechanism of Action Jakavi 20mg (Ruxolitinib 20mg)

Ruxolitinib is also knowns kinase inhibitor which is discriminating for the Janus analogue Kinases (JAK) 1 and 2. These kinases are required for the mediation of cytokine and growth factor signalling which in turn effect immune function and hematopoiesis.
The communicate process involves signal transducers and transcription activators (STAT) that modulate gene expression. Patients having myelofibrosis consist of abnormal JAK1 and JAK2 activity,Therefore Ruxolitinibfunction to regulate this.

Absorption of Jakavi 20mg (Ruxolitinib 20mg)

Fast absorption and not affected by food maximum plasma level is 1.5 hours.

Distribution of Jakavi 20mg (Ruxolitinib 20mg)

volume of distribution is 76.6 L plasma protein binding

Metabolism of Jakavi 20mg (Ruxolitinib 20mg)

Jakavi metabolized by CYP3A4

Excretion of Jakavi 20mg (Ruxolitinib 20mg)

Jakavi eliminatedvia urine 74% and unchanged medicine is <1% and through urine 22% ,<1 % as unchanged medicine.

Side effects of Jakavi 20mg (Ruxolitinib 20mg)

Side effects caused due to Jakavi 20mg (Ruxolitinib 20mg)

  • Bruising
  • Swelling
  • Neutropenia
  • Dizziness
  • Increased cholesterol
  • Shortness of breath
  • Nasopharyngitis
  • Anemia
  • Thrombocytopenia
  • Increased liver enzymes
  • Diarrhea
  • Headache
  • Constipation
  • Nausea & Vomiting
  • Insomnia.

Precautions of Jakavi 20mg (Ruxolitinib 20mg)

Treatment with Jakavi 20mg (Ruxolitinib 20mg) can resulted in thrombocytopenia, Anemia and neutropenia. Control thrombocytopenia by decreasing the dose or temporarily interfere with Jakavi 20mg (Ruxolitinib 20mg). Platelet transfusions may be necessary.

Risk of infection occurs by delay initiate treatment with Jakavi 20mg (Ruxolitinib 20mg) until active severe infection have resolved.
Tuberculosis infection has been reported in patients receiving Jakavi 20mg (Ruxolitinib 20mg). Observe patients receiving Jakavi 20mg (Ruxolitinib 20mg) for signs and symptoms of active tuberculosis and manage promptly.
Progressive multifocal leukoencephalopathy (PML) has occurred with Jakavi 20mg (Ruxolitinib 20mg)treatment. If PML is suspected, stop Jakavi 20mg (Ruxolitinib 20mg) and evaluate Non-melanoma skin cancers including basal cell, squamous cell, and Merkel cell carcinoma have occurred in patients treated with Jakavi 20mg (Ruxolitinib 20mg). Perform periodic skin examinations.

Drug interaction of Jakavi 20mg (Ruxolitinib 20mg)

Concomitant use with fluconazole doses greater than 200mg daily may increase Ruxolitinib exposure leads to increase the risks of exposure related adverse reaction.

Interaction of Jakavi 20mg (Ruxolitinib 20mg) with strong CYP3A4 inhibitors will increases Ruxolitinib exposure.

Interaction of Jakavi 20mg (Ruxolitinib 20mg) with strong CYP3A4 inducers will decreases Ruxolitinib exposure.

Contraindication of Jakavi 20mg (Ruxolitinib 20mg)


Pregnancy of Jakavi 20mg (Ruxolitinib 20mg)

There are no studies with the use of Jakavi 20mg (Ruxolitinib 20mg) in pregnant women to inform medicine-associated risks.

Avoid becoming pregnancy during Jakavi 20mg (Ruxolitinib 20mg) treatment

Lactation of Jakavi 20mg (Ruxolitinib 20mg)

Excretion into human milk is unknown

Avoid breast feeding during treatment with Jakavi 20mg (Ruxolitinib 20mg)

Dosage of Jakavi 20mg (Ruxolitinib 20mg)

Myelofibrosis :

Kinase inhibitor uses for treatment of patients with intermediate or high-risk myelofibrosis, involving mainly myelofibrosis, post-polycythemiavera myelofibrosis and post-essential thrombocythemia myelofibrosis

Starting recommended doses for myelofibrosis:

If Platelet count >200 x10^9/L the dose given is 20 mg PO BID

If Platelet count 100-200 x10^9/L the dose given is 15 mg PO BID

If Platelet count 50 to <100 x10^9/L the dose given is 5 mg PO BID

Titrate dose based on response; not to exceed 25 mg PO BID.

Polycythemia Vera :

The recommended dose is 10mg PO BID
Undergo CBC and platelet count prior starting and q2-4wk until doses are stabilized, and then as clinically used.

Storage of Jakavi 20mg (Ruxolitinib 20mg)

Jakavi 20mg (Ruxolitinib 20mg) stored at 20℃ to 25℃
Protect away from light and moisture
Dispense in its original container

Missed dose of Jakavi 20mg (Ruxolitinib 20mg)

If dose is missed the have the dose immediately before next dose timing reaches or skip the missed dose and continue the regular schedule.Consult doctors regarding missed dose. Avoid taking double the dose.

Brand name:
International trade name:
Active substance:
Anti Cancer
14 Tablets
Product form:

No reviews found

Write feedback
Worldwide delivery

Our company ships from India to all countries of the world.

Genuine and Authentic products

All products supplied from the manufacturer of WHO : GMP certified facilities and ISO Certified facilitates

Economical and Affordable prices

All the products are supplying from manufacturing companies of India